A Phase I, single center, randomized, open-label study investigating the effect of formulation, and active pharmaceutical ingredient particle size on the pharmacokinetics of fenebrutinib in healthy subjects
Latest Information Update: 12 Sep 2023
At a glance
- Drugs Fenebrutinib (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Acronyms QSC206109
- Sponsors Genentech
- 17 Aug 2022 According to ISRCTN, the recruitment is expected to end by 10/09/2023.
- 17 Aug 2022 New trial record
- 11 Aug 2022 Status changed from recruiting to completed.